title: Antiretroviral therapy and pregnancy: effect on cortical bone status of human immunodeficiency virus-infected Caucasian women as assessed by quantitative ultrasonography.
abstract: Treatment with antiretroviral agents (ARVs) during pregnancy is important to prevent mother-to-child transmission of the human immunodeficiency virus (HIV), but their use has been associated with low bone mineral density in adult patients. Currently, there are no data regarding the bone status of HIV-infected women who received ARV during pregnancy. The aim of this study was to evaluate cortical bone status at delivery in a group of HIV-infected women who received ARV during pregnancy and to monitor the changes occurring during the first year postpartum. We studied 33 HIV-infected and 116 HIV-uninfected healthy Caucasian women within 4 days from delivery. Follow-up measurements were performed at 4 and 12 months postpartum in 17 HIV-infected and 55 healthy women. Cortical bone status was evaluated by quantitative ultrasonography at the mid-tibia, and bone measurements were expressed as the speed of sound (SOS). HIV-infected women after delivery had a median SOS of 3,985 (3,567-4,242) m/s, while the median SOS of healthy women was 4,025 (3,643-4,250) m/s. The difference was not significant (t = 0.39, P = 0.69). No significant differences were observed between ARV-exposed and control subjects at 4 and 12 months. Our data suggest that ARV during pregnancy and the first year after delivery does not affect negatively cortical bone status.
authors.affiliation: Laboratory of Pediatric Endocrinology, BoNetwork, Division of Metabolic and Cardiovascular Sciences, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. mora.stefano@hsr.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Mora
authors.forename: Cecilia
authors.initials: C
authors.lastname: Diceglie
authors.forename: Alessandra
authors.initials: A
authors.lastname: Viganò
authors.forename: Vania
authors.initials: V
authors.lastname: Giacomet
authors.forename: Valeria
authors.initials: V
authors.lastname: Manfredini
authors.forename: Sara
authors.initials: S
authors.lastname: Stucchi
authors.forename: Valentina
authors.initials: V
authors.lastname: Fabiano
authors.forename: Chiara
authors.initials: C
authors.lastname: Mameli
authors.forename: Sonia
authors.initials: S
authors.lastname: Coletto
authors.forename: Gian V
authors.initials: GV
authors.lastname: Zuccotti
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000187:drug effects; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008137:Longitudinal Studies; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D013977:Tibia / Q000000981:diagnostic imaging / Q000187:drug effects; D014463:Ultrasonography; D044465:White People
chemical_list: D044966:Anti-Retroviral Agents